Gene therapies promise to solve more than 6,500 diseases
... so why are millions of patients waiting for a therapy?
… because precise delivery has not been solved yet!
Getting the gene therapies in to the right cells is the largest obstacle to success
We deliver gene therapies using electromagnetic waves
Our electromagnetic waves create pores in the membranes of the target cells, enabling gene therapies to go in
We have proven our technology in mice
Experiments show effective delivery of gene therapies, when using our specially designed electromagnetic waves
Pharma will license our technology to unlock delivery in patients
Our technology will enable pharma to bring gene therapies to market that are not possible with current technologies such as viral vectors and nanoparticles
Delivery technology is key to the success of gene therapies – a market with 23% CAGR
We already have ...
Path to marketA clear path to selling first lab devices to early customers
Customer engagementEarly engagement with potential customers with two MTAs signed
Proof of conceptInitial first-of-its-kind data demonstrating that our technology can be used to deliver gene therapies
With $500k and 18 months, we can get...
Production readyPrototype of lab device ready for commercial production
First pilot projectSigned pilot agreement with potential customer (pre-cursor to license agreement)
We have the skills to execute: Domain specialists ...
CEO, co-founder Niels Clausen
DTU, The University of Texas, The University of Auckland
Science, co-founder Carl Frederik Haugaard
University of Copenhagen, University of Oxford, Region H
Technology, co-founder Thomas Smith
Lars Thrane Communication Systems, DTU, Cobham Satcom
… and deep biotech experience
Chair of the board, Jörn Aldag
UniQure, Hookipa Pharma, Evotec
Exec. advisor, co-founder Alexander Viterbo-Horten
PreSeed Ventures, DTU, PA